(Adnkronos) - Con la conferenza stampa ‘Tumori del sangue: le nuove frontiere del trattamento dal Congresso della Società Americana di Ematologia’ AstraZeneca ha presentato i risultati dello studio Echo, che studia l’efficacia di acalabrutinib in combinazione con chemio-immunoterapia nel trattamento di prima linea di pazienti over 65 con linfoma mantellare, e dello studio clinico di fase III Amplify, sull’impiego di acalabrutinib e venetoclax come primo regime completamente orale a durata fissa di un inibitore della tirosin-chinasi di Bruton di seconda generazione nel trattamento di prima linea della leucemia linfatica cronica, vincitore del riconoscimento Best of Ash 2024.
Category
🗞
NewsTranscript
00:00With the press conference, blood tumors and the new frontiers of treatment by the Congress
00:08of the American Society of Hematology, AstraZeneca illustrated in Milan the results of two important
00:13clinical studies presented at the ASH 2024 Congress, the 66th Congress of the American
00:20Society of Hematology.
00:21Inscribed with the Best of ASH award, the Phase III Amplify clinical study highlights
00:26the potential of a new therapeutic frontier in the treatment of chronic lymphatic leukemia.
00:31The study examines the effectiveness of acalabrutinib and venetoclax as the first fixed-duration
00:35oral regimen of a second-generation bruton-bending thyrosine inhibitor in the treatment of
00:40oncological pathology.
00:41The study has shown that the arms that we have with acalabrutinib and venetoclax have
00:48a better survival free of progression compared to immunotherapy, even the survival
00:54free of disease has been reached with immunotherapy and while three years ago with acalabrutinib
01:01and venetoclax it was 77% or 83% when we also combine the monoclonal antibody.
01:08This is seen above all in patients at higher risk with non-mutated immunoglobulin characteristics
01:14at the surface level, who have a slightly more cheerful disease, let's say, in quotes,
01:18compared to mutated patients and it is a bit early to talk about survival, but we also have
01:24a better survival of acalabrutinib and venetoclax compared to immunotherapy.
01:30At the ASHA Congress, the updated results of the ECHO study on acalabrutinib and venetoclax
01:36in combination with chemoimmunotherapy have also been presented in the first-line treatment
01:39of patients over 65 with lymphoma mantleare.
01:42The study has brought very satisfactory results, in the sense that the innovative therapy associated
01:51with chemoimmunotherapy, with acalabrutinib, has shown an improvement in patients in the first line,
01:58therefore not previously treated, both in the progression free of disease and with a strong trend
02:05also in relation to global survival.
02:08So, this association, which has also been little toxic compared to what could have been expected
02:15from a similar combination of several drugs, will likely become a new standard of therapy
02:24in lymphoma mantleare patients over 65, therefore adults and seniors, and will represent a new step
02:34in the improvement of global survival in this important hematological pathology.
02:40But the commitment of AstraZeneca in the hematological field is even greater.
02:44We have entered this area, which is super-specialistic, therefore really very complex,
02:50and in this area we want to continue to bring innovation and research, and this is what we are doing.
02:55With more than 100 studies in oncology in Italy, almost 10% are in hematology
03:01and above all they continue to grow over the years, so we do not stop here, we have new molecules
03:06and above all we want to go to new pathologies, where we want to bring our contribution
03:11to take steps forward and we hope to have other successes in this field.